Outcome of Modified St Jude Total Therapy 13A for Childhood Acute Lymphoblastic Leukemia in the Southeast Region of Turkey

Köç, Ahmet; Ayçicek, Ali; Özdemir, Zeynep Canan; Söker, Murat; Varma, Mustafa

doi:10.1097/mph.0b013e318271f43f

Cited by 10 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Dujua and Hernandez (16) from the Philippines, the rate of male ALL cases was found to be 61.5%. In some studies conducted in our country, ALL was reported to be more common in male, while in some studies, it was reported to be more common in female (17,18). In our study, 86 of the 129 patients (66%) were male, 43 (33%) were girls and the male/female ratio was 2/1.…”

Section: Discussionsupporting

confidence: 43%

Overall and Event-free Survival in Children with Acute Lymphoblastic Leukemia and Evaluation of Treatment Related Acute Toxicity

Özdoğan¹,

Ayçicek²,

Tekgündüz³

et al. 2022

csmedj

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 43%

Overall and Event-free Survival in Children with Acute Lymphoblastic Leukemia and Evaluation of Treatment Related Acute Toxicity

Özdoğan¹,

Ayçicek²,

Tekgündüz³

et al. 2022

csmedj

View full text Add to dashboard Cite

show abstract

“…In Turkey, a similar Total XIII protocol was adopted and the 5‐year EFS was 77%. The induction death was 12.3% and infection was the most important cause of death . In India, septicemia was also reported to be an important cause of death, accounting for 29.7% of deaths .…”

Section: Discussionmentioning

confidence: 99%

“…The induction death was 12.3% and infection was the most important cause of death. 12 In India, septicemia was also reported to be an important cause of death, accounting for 29.7% of deaths. 13 In the multicenter report of ALL from China, non-relapse mortality during remission was 2.9% and infection was the cause of death in 73.4%.…”

Section: Discussionmentioning

confidence: 99%

Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG‐ALL‐2015

et al. 2020

View full text Add to dashboard Cite

Background Septicemia is an important cause of treatment‐related mortality and treatment failure in pediatric acute lymphoblastic leukemia (ALL) in developing countries. A multicenter CCCG‐ALL‐2015 study was conducted in China and factors associated with septicemia and mortality were studied. Methods Patients participated in CCCG‐ALL‐2015 study from January 2015 to December 2017 were included. Patients with documented septicemia were identified from the Data Center and additional data were collected. Results A total of 4080 patients were recruited in the study and 527 patients with septicemia were identified (12.9%, 95% CI 11.9%‐13.9%). The intermediate risk (IR)/high risk (HR) group had significantly higher incidence of septicemia as compared with low risk (LR) group, 17.1% vs 9.1% (OR 2.07, 95% CI 1.71‐2.49, P < .001). Induction phase was the period with majority of septicemia episodes happened, 66.8% in LR and 56.1% in IR/HR groups. Gram‐positive bacteria accounted for 54.1%, gram‐negative bacteria 44.5%, and fungus 1.4% of positive cultures. Multidrug‐resistant organisms were detected in 20.5% of all organisms. The mortality rate after septicemia was 3.4% (95% CI 1.9%‐4.9%). Multiple logistic regression identified female gender, comorbid complications, and fungal infection as risk factors associated with mortality. Gram‐negative septicemia was associated with higher mortality, 4.9% vs 1.4% (OR 0.28, 95% CI 0.09‐0.88, P = .02). There was marked variation in the incidence of septicemia among the 18 centers, from 4.8% to 29.1%. Conclusion Overall the incidence and pattern of septicemia in this multicenter study in China was similar to the reports of western countries. The septicemia‐related mortality rate was low. There was marked variation in the incidence of septicemia among the centers.

show abstract

“…We could not identify any source assessing which treatment protocols are used in pediatric oncology departments across each of the four jurisdictions. However, a number of clinical outcomes studies refer to the use of a range of international protocols, with or without adaptations, such as Berlin-Frankfurt-Munster, 42 , 43 Children’s Cancer Group, Children’s Oncology Group, 44 , 45 St Jude Total, 46 , 47 National Wilms Tumor Study 48 ; or national protocols (eg, in Turkey). 49 , 50 Turkey appears to be the only country in the sample where a national-level professional association (Turkish Pediatric Oncology Group) produces treatment protocols and guidelines, and conducts studies to assess their outcomes.…”

Section: Resultsmentioning

confidence: 99%

Economics of Pediatric Cancer in Four Eastern Mediterranean Countries: A Comparative Assessment

Gheorghe

Chalkidou

Shamieh

et al. 2020

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE Cancer is a leading cause of death among children in the Eastern Mediterranean region, where conflict and economic downturn place additional burden on the health sector. In this context, using economic evidence to inform policy decisions is crucial for maximizing health outcomes from available resources. We summarized the available evidence on the economics of pediatric cancer in Jordan, Lebanon, the occupied Palestinian territory, and Turkey. METHODS A scoping review was performed of seven academic databases and gray literature pertaining to pediatric cancer in the four jurisdictions, published between January 1, 2010, and July 17, 2019. Information was extracted and organized using an analytical framework that synthesizes economic information on four dimensions: the context of the health system, the economics of health care inputs, the economics of service provision, and the economic consequences of disease. RESULTS Most of the economic evidence available across the four jurisdictions pertains to the availability of health care inputs (ie, drugs, human resources, cancer registration data, and treatment protocols) and individual-level outcomes (either clinical or health-related quality of life). We identified little evidence on the efficiency or quality of health care inputs and of pediatric cancer services. Moreover, we identified no studies examining the cost-effectiveness of any intervention, program, or treatment protocol. Evidence on the economic consequences of pediatric cancer on families and the society at large was predominantly qualitative. CONCLUSION The available economic evidence on pediatric cancer care in the four countries is limited to resource availability and, to an extent, patient outcomes, with a substantial gap in information on drug quality, service provision efficiency, and cost-effectiveness. Links between researchers and policymakers must be strengthened if pediatric cancer spending decisions, and, ultimately, treatment outcomes, are to improve.

show abstract

Outcome of Modified St Jude Total Therapy 13A for Childhood Acute Lymphoblastic Leukemia in the Southeast Region of Turkey

Abstract: St Jude Total 13A treatment protocols to treat childhood ALL can be successfully adapted, which suggests that such an approach may be useful in low socioeconomic regions; however, it should be noted that secondary leukemia can occur at a high rate.

Cited by 10 publications

References 30 publications

Overall and Event-free Survival in Children with Acute Lymphoblastic Leukemia and Evaluation of Treatment Related Acute Toxicity

Overall and Event-free Survival in Children with Acute Lymphoblastic Leukemia and Evaluation of Treatment Related Acute Toxicity

Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG‐ALL‐2015

Economics of Pediatric Cancer in Four Eastern Mediterranean Countries: A Comparative Assessment

Contact Info

Product

Resources

About